Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Partnership for Applied Research in Fracture Prevention Programs for the Elderly (OPTI-FRAC)

26. Oktober 2018 aktualisiert von: Isabelle Gaboury, Université de Sherbrooke
During their lifetime, approximately 50% of Canadian women and 30% of Canadian men will experience at least one fracture due to bone fragility (FF). Evidence is growing regarding prevention programs' effectiveness to prevent falls, but prevention of fractures through fall prevention programs has enjoyed limited success. Falls prevention programs and post-fracture screening programs leading to pharmacological treatment are very different strategies, with a shared ultimate goal. Coordination between those who repair fractures and those who manage the patient to prevent the next fracture is critical. The overarching aim of this proposal is to generate evidence-based knowledge about the effectiveness and cost-effectiveness of an integrated FF prevention program, as well as a portrait of the barriers and facilitating factors for such programs. More specifically, the objectives are: 1) to combine existing fall prevention and post-fracture management programs in the province of Quebec into integrated FF prevention programs; 2) to compare the performance of these integrated programs to control sites, using a pragmatic study design; 3) to identify barriers as well as factors that improve effectiveness across different implementation milieu; and 4) to develop and engage in active knowledge transfer activities in Quebec regions where integrated FF prevention programs are neither adequately nor successfully implemented. Drawing upon the literature on integrated healthcare, fall and fracture prevention, we hypothesize that an integrated FF program can reduce the risk of a subsequent fracture by at least 30% in the population of interest. The proposed team is poised to develop new interdisciplinary collaborations among healthcare practitioners and decision makers involved in the prevention of FFs. The program is built upon existing healthcare and structures and programs and in turn, will truly measure the effectiveness of an integrated FF prevention program. The results will ultimately lead to improvements in the existing knowledge base, address policy-relevant and health systems problems, and assist in the design and implementation of FFs prevention programs.

Studienübersicht

Status

Unbekannt

Bedingungen

Intervention / Behandlung

Studientyp

Interventionell

Einschreibung (Tatsächlich)

631

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

  • Kanada
    • Quebec
      • Amos, Quebec, Kanada, J9T 2S2
        • Centre hospitalier Hôtel-Dieu d'Amos
      • Chandler, Quebec, Kanada, G0C 1K0
        • CSSS du Roché Percé (Centre hospitalier de Chandler)
      • Gatineau, Quebec, Kanada, J8Y 1W7
        • Hôpital de Hull
      • Greenfield Park, Quebec, Kanada, J4V 2H1
        • Hopital Charles LeMoyne
      • Montreal, Quebec, Kanada, H1T 2M4
        • Hôpital Maisonneuve-Rosemont
      • Montreal, Quebec, Kanada, H4J 1C5
        • Hopital Sacre-Coeur de Montreal
      • Montreal, Quebec, Kanada, H2E1S6
        • Hôpital Jean-Talon
      • Saint-Charles-Borromée, Quebec, Kanada, J6E 6J2
        • Centre hospitalier régional de Lanaudière
      • Sherbrooke, Quebec, Kanada, J1H5N4
        • Centre Hospitalier Universitaire de Sherbrooke
      • St-Jérôme, Quebec, Kanada, J7Z 5T3
        • CSSS de St-Jérôme (Hôpital régional de St-Jérôme)

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

50 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • 50 years of age and over
  • must have a primary care physician
  • must be able to follow simple instructions
  • must have sustained a fragility fracture within three months of the recruitment date.

Exclusion Criteria:

  • severe kidney insufficiency (grade 4 or 5)
  • advanced stage of cancer
  • fracture to sites not commonly associated with osteoporosis such as toe, finger, hand, foot, ankle, patella, head, and cervical spine.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Versorgungsforschung
  • Zuteilung: Nicht randomisiert
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Kein Eingriff: Kontrollgruppe
Experimental: Integrated program
Participants will be involved in an integrated interorganisational fragility fracture prevention program, which combines both post-fracture management as well as fall prevention strategies. The intervention will last up to 18 months.
Sonstiges: Integrated program
Each participant's primary care physician will receive written information containing a presumed osteoporosis diagnosis, investigations to be performed, correct interpretation of any bone densitometry results in the context of a fragility fracture, and treatment options. The study coordinator will be responsible for orienting the participant to an appropriate local fall prevention program.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Zeitfenster
Incidence of secondary fragility fracture
Zeitfenster: 18 months post recruitment
18 months post recruitment

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Initiation of osteoporosis treatment by the primary care physician
Zeitfenster: At 6, 12, 18, and 60 months post recruitment
Osteoporosis treatment includes bisphosphonates or other effective osteoporosis drugs.
At 6, 12, 18, and 60 months post recruitment
Compliance with osteoporosis treatment.
Zeitfenster: At 6, 12, 18, and 60 months post recruitment
The data collected from the participant will be validated with the participant's pharmacist through the medication possession ratio. The medication possession ratio is measured from the first to the last prescription, with the denominator being the duration from index to the exhaustion of the last prescription and the numerator being the days supplied over that period from first to last prescription and the numerator being the total number of days in the interval.
At 6, 12, 18, and 60 months post recruitment
Time to first fall event
Zeitfenster: Within the first 18 months post recruitment
Within the first 18 months post recruitment
Incidence of secondary fragility fractures.
Zeitfenster: At 24, 36, 48 and 60 months post recruitment
At 24, 36, 48 and 60 months post recruitment
Number of clinically significant fall events.
Zeitfenster: At 18, 24, 36, 48 and 60 months post recruitment
At 18, 24, 36, 48 and 60 months post recruitment
Fall-related hospitalizations
Zeitfenster: At 18, 24, 36, 48 and 60 months post recruitment
Fall-related hospitalizations will be recorded in the participant diary and at each telephone follow-up, and validated with the participant's hospital records.
At 18, 24, 36, 48 and 60 months post recruitment
Fragility fracture-related death
Zeitfenster: At 18, 24, 36, 48 and 60 months post recruitment
Fragility fracture-related death will be confirmed from a provincial administrative database (Regie de l'assurance maladie du Quebec - RAMQ).
At 18, 24, 36, 48 and 60 months post recruitment
Participants' quality of life
Zeitfenster: At 18, 24, 36, 48 and 60 months post recruitment
Euro-QOL
At 18, 24, 36, 48 and 60 months post recruitment
Practice of physical activities
Zeitfenster: At 6, 12, 18, 24, 36, 48 and 60 months post recruitment
CHAMPS
At 6, 12, 18, 24, 36, 48 and 60 months post recruitment
Fragility fracture-related costs
Zeitfenster: At 18 and 60 months post recruitment
Medical costs from the participant's hospital record include: medical assessment, prescription and non-prescription drugs; and resource use related to the management of the fragility fracture and/or long-term complications, including hospitalization. As well, lost days of work, annual income (if the participant is in the labour force), travel to the hospital and/or rehabilitation facilities, parking, and out-of-pocket expenses for drugs and rehabilitation devices (e.g. splint) will be compiled. Protocol-driven costs will be excluded, with the exception of the costs related to the participants' fall prevention program.
At 18 and 60 months post recruitment
Admission to a long-term care facility
Zeitfenster: At 18, 24, 36, 48 and 60 months post recruitment
At 18, 24, 36, 48 and 60 months post recruitment
Participants' perceptions of care integration
Zeitfenster: At 12 months post intervention
All participants' perceptions of care integration will be captured 12 months after the beginning of the intervention period, or following an early withdrawal from the study.
At 12 months post intervention
Intervention participant's satisfaction with the fragility fracture prevention program
Zeitfenster: At 12 months post intervention
At 12 months post intervention

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Université de Sherbrooke

Mitarbeiter

Merck Sharp & Dohme LLC
Novartis
Canadian Institutes of Health Research (CIHR)
Amgen
Ministere de la Sante et des Services Sociaux
CSSS-IUGS Estrie

Ermittler

  • Hauptermittler: Isabelle Gaboury, PhD, Université de Sherbrooke
  • Hauptermittler: Hélène Corriveau, PhD pht, Université de Sherbrooke

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Allgemeine Veröffentlichungen

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn

1. Januar 2013

Primärer Abschluss (Tatsächlich)

1. November 2016

Studienabschluss (Voraussichtlich)

1. Juni 2019

Studienanmeldedaten

Zuerst eingereicht

5. Dezember 2012

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

5. Dezember 2012

Zuerst gepostet (Schätzen)

7. Dezember 2012

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

29. Oktober 2018

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

26. Oktober 2018

Zuletzt verifiziert

1. Oktober 2018

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Schlüsselwörter

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • CIHR grant # 267395

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Integrated program

Suchen Sie nach ähnlichen Studien

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

CROs by country

CROs in Suriname

Bedingungen

Seltene Krankheiten

Drogeninterventionen

Nahrungsergänzungsmittel

Sponsor / Mitarbeiter

Standorte

Abonnieren